AMPH and small cell lung carcinoma: NSCLC was found to be the most frequent among anti-Hu (12/32, 37.5%) and anti-GABABR (6/22, 27.3%) antibodies, while SCLC was the most common among anti-CV2 (3/10, 30.0%) and anti-amphiphysin antibodies (2/5, 40%).